Sodium glucose co-transporter-2 inhibitors in intensive care unit patients with type 2 diabetes: a pilot case control study

Sodium glucose co-transporter-2 inhibitors in intensive care unit patients with type 2 diabetes: a pilot case control study

Abstract Background Sodium glucose co-transporter-2 (SGLT2) inhibitors improve long-term cardiovascular and renal outcomes in individuals with type 2 diabetes. However, the safety of SGLT2 inhibitors in ICU patients with type 2 diabetes is uncertain. We aimed to perform a pilot study to assess the r...

Full description

Bibliographic Details
Main Authors: Johan Mårtensson, Salvatore Lucio Cutuli, Eduardo A. Osawa, Fumitaka Yanase, Lisa Toh, Luca Cioccari, Nora Luethi, Akinori Maeda, Rinaldo Bellomo
Format: Article
Language:English
Published: BMC 2023-05-01
Series:Critical Care
Subjects:
SGLT2 inhibitor
Empagliflozin
Intensive care
Diabetes
Online Access:https://doi.org/10.1186/s13054-023-04481-y

Internet

https://doi.org/10.1186/s13054-023-04481-y

Similar Items